AMGN stock forecast, quote, news & analysis

Key Takeaways

• Amgen shares pulled back roughly 9% over the trailing 30 days, retreating from about $416 in mid-August to near $377 by early September.
• The decline was driven by a read-through from Novartis (NVS), whose pelacarsen therapy missed its Phase 3 cardiovascular-outcomes endpoint, raising questions about Amgen's own Lp(a) program, olpasiran.
• The stock fell 10.08% on September 8, 2026 — its worst single-day decline since 2000 — as multiple analysts trimmed their ratings.
• Amgen's fundamentals remain intact, with second-quarter revenue up 10% to roughly $10.1 billion and full-year guidance reaffirmed.
• Longer-term catalysts, including the MariTide obesity program and the olpasiran outcomes trial, remain key watch items for investors.

Current Market Snapshot

Amgen entered September 2026 on a strong footing, having rallied more than 30% year to date before a sharp mid-month pullback. The shares traded near $377 after falling from levels above $437, yet they remain well off the 52-week low of $269.77 and below the 52-week high of $447.03. The stock carries a dividend yield near 2.6% and a market capitalization above $200 billion, reflecting its standing as one of the world's largest independent biotechnology companies.

The recent weakness was narrow in nature — tied to cardiovascular pipeline sentiment rather than a deterioration in the company's commercial business. Short interest remains modest at roughly 2% of the float, and institutional ownership held broadly steady through the second quarter, suggesting the selloff was driven by a specific clinical read-across rather than a broad repositioning away from the name.

Amgen Inc. (AMGN) Business Overview and Competitive Position

Amgen is a global leader in biotechnology-based human therapeutics, spanning inflammation, oncology, bone health, cardiovascular disease, and rare diseases. Its franchise includes long-standing products such as Enbrel, Otezla, Prolia, Xgeva, Neulasta, and Aranesp, alongside newer growth drivers like the cholesterol-lowering therapy Repatha and the severe asthma drug Tezspire.

The 2023 acquisition of Horizon Therapeutics broadened Amgen's rare-disease portfolio, most notably adding the thyroid eye disease treatment Tepezza. The company has also built a growing biosimilars business, which helps offset the impact of patent expirations across its mature brands. Investors follow Amgen for its diversified revenue base, strong cash flow, and an advancing pipeline anchored by the obesity candidate MariTide and the investigational Lp(a) therapy olpasiran.

Recent Developments Driving AMGN

The dominant catalyst in recent weeks came from outside Amgen. On September 4, 2026, Novartis (NVS) and Ionis Pharmaceuticals (IONS) announced that pelacarsen, an Lp(a)-lowering therapy, failed to reduce cardiovascular events in the Phase 3 Lp(a)HORIZON trial despite substantially lowering Lp(a) levels. Because Amgen's olpasiran targets the same biological premise, investors immediately repriced the odds of success for Amgen's program.

The read-through triggered a 10.08% one-day decline on September 8, the stock's steepest since 2000. BMO Capital downgraded Amgen to Market Perform from Outperform while keeping a $450 price target, and HSBC cut its rating to Hold with a $425 target. Amgen's own Phase 3 OCEAN(a)-Outcomes trial for olpasiran remains ongoing, with data not expected until 2028.

Offsetting the negative sentiment, Amgen reported on August 31 that a prespecified VESALIUS-CV analysis showed Repatha reduced the risk of death by 20% in high-risk patients, reinforcing a key commercial growth driver. Second-quarter results, reported in early August, showed total revenue up 10% to about $10.1 billion, with management reaffirming 2026 revenue guidance of $38.2 billion to $39.4 billion.

Trending AI Robots

For traders seeking a data-driven perspective on names like Amgen, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. The bots vary by strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term signals to longer-horizon models. Browsing the list can help traders evaluate how systematic, algorithm-driven strategies are positioning across sectors, including healthcare and biotechnology. Explore the page to see which AI-powered strategies are currently trending.

2026 Outlook and What Investors Should Watch

Looking ahead, the most consequential variable for Amgen is the fate of olpasiran. While Novartis's failure does not directly determine Amgen's outcome — olpasiran achieved deeper Lp(a) reductions in earlier studies and uses a different molecule — the broader hypothesis that lowering Lp(a) reduces cardiovascular events now faces heightened scrutiny. Detailed results from the Novartis trial are expected at a medical conference later in 2026, and any clarity there could again move Amgen's stock.

Investors should also monitor the MariTide obesity program, where competitive positioning against established incretin-based therapies from Eli Lilly (LLY) and others will be a key determinant of the pipeline's value. On the commercial side, loss of exclusivity for mature products, pricing pressure, and biosimilar competition represent ongoing headwinds that management has flagged. Amgen's next quarterly report and any updates to full-year guidance will provide the clearest signal on whether the company can sustain its revenue momentum through these pressures.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations